Skip to main content

JHOP - February 2023 Vol 13, No 1

Case Reports
Original Research
Practical Issues in Pharmacy Management
FDA Updates
Perspective
Case Reports
Case Reports, Infections, COVID-19
A Pregnant 19-Year-Old Patient with Refractory Immune Thrombocytopenia and Concomitant SARS-CoV-2 Infection: Case Report
Rebecca Rezac, PharmD, and Jaimie Wittig, PharmD, BCOP
Read More
Case Reports, Lymphoma, CAR T-Cell Therapy, Adverse Events
Anakinra Used in a Patient with Diffuse Large B-Cell Lymphoma and Steroid-Refractory Immune Effector Cell–Associated Neurotoxicity Syndrome: Case Report
Drew A. Wells, PharmD, BCPS; Kori Holman, PharmD, BCOP; Brion Randolph, MD; Dennis Marjoncu, PharmD, BCOP
Read More
Original Research
Original Research, Biosimilars, Pediatric Cancer, Transplant, Chemotherapy
Comparing the Efficacy and Safety of Reference Drug Filgrastim and Biosimilar Filgrastim-sndz in Pediatric Patients Used for Post–Hematopoietic Stem-Cell Transplant Engraftment or Chemotherapy-Induced Febrile Neutropenia Prophylaxis
Cassandra Rush, PharmD; Ashley Sabus, PharmD, BCOP; Obehi Enabulele, PharmD, MBA, MS; Abby Kim, BA, PharmD, BCOP
Read More
Original Research, Targeted Therapies, Screening
Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San Diego
Mina Nikanjam, MD, PhD; Jose Tinajero, PharmD; Mary McGann, PharmD, BCOP; Jerry Li, PharmD; Jincheng Yang, PharmD; Felicity Shen, PharmD; Jason K. Sicklick, MD; Shumei Kato, MD; Edmund Capparelli, PharmD; Razelle Kurzrock, MD
Read More
Original Research, Leukemia, Lymphoma, Adverse Events
Economic Burden of Cardiovascular Events in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the First Year After Initiating Treatment with a Novel Agent
Elisabetta Malangone-Monaco, DrPH; Kellie Ryan, MPH; Elizabeth H. Marchlewicz, PhD, MPH, RD; Joyce Lo, PharmD; Scott Huntington, MD, MPH
Read More
Practical Issues in Pharmacy Management
Practical Issues in Pharmacy Management, Oncology Pharmacy Programs/Protocols, Transplant
Cost-Savings Using Patients’ Own Medication Supply of Letermovir for Allogeneic Hematopoietic Stem-Cell Transplant Recipients During Hospitalization
Harrison S. Yoon, PharmD; Mallory Crain, PharmD, BCOP; Marissa Olson, PharmD, BCOP; Anupam Pande, MD, MPH; Jeff O. Klaus, PharmD, BCPS
Read More
FDA Updates
FDA Updates
Orserdu FDA Approved for ER-Positive Advanced or Metastatic Breast Cancer with ESR1 Mutation
Read More
FDA Updates
Jaypirca, a New BTK Inhibitor, Received FDA Accelerated Approval for Relapsed or Refractory Mantle-Cell Lymphoma
Read More
FDA Updates
FDA Approved Lunsumio for Relapsed or Refractory Follicular Lymphoma
Read More
FDA Updates
Adstiladrin, First Adenoviral Vector–Based Gene Therapy, FDA Approved for High-Risk Non–Muscle Invasive Bladder Cancer
Read More
FDA Updates
Krazati Received Accelerated FDA Approval for NSCLC with KRAS G12C Mutation
Read More
Online Only
FDA Updates
Keytruda Received FDA Approval for Adjuvant Treatment of Non–Small-Cell Lung Cancer
Read More
Online Only
FDA Updates
Tukysa, in Combination with Trastuzumab, Now FDA Approved for HER2-Positive Unresectable or Metastatic Colorectal Cancer
Read More
Online Only
FDA Updates
Brukinsa Now FDA Approved for Patients with CLL or SLL
Read More
Online Only
FDA Updates
Tecentriq Now FDA Approved for Treatment of Alveolar Soft-Part Sarcoma
Read More
Perspective
Perspective
“You Have Cancer”
Joshua N. Raub, PharmD, BCPS
Read More